The non-canonical role of vascular endothelial growth factor-C axis in cancer progression

Abstract

It has been shown in many clinical studies that the level of vascular endothelial growth factor-C (VEGF-C) positively correlates with lymph node metastasis. Nevertheless, beyond the canonical role of VEGF-C in stimulating lymphangiogenesis and thus promoting lymph node/distant metastasis, emerging evidence indicates that expression of VEGF-C contributes to various aspects of carcinogenicity via autocrine regulation. The newly identified functions of VEGF-C include but are not limited to proliferation, migration, invasion, and chemo-resistance. Besides tumor cell autocrine regulation, VEGF-C can also modulate the immune system such that tumor cells more easily escape immune surveillance. Therefore, understanding the functional roles and regulatory mechanisms related to the VEGF-C axis may lead to alternative strategies for cancer treatment. This mini-review will focus on summarizing recent discoveries regarding the unconventional functions of VEGF-C in cancer progression.

Keywords

Vascular endothelial growth factor-C autocrine cancer stem cells drug resistance lymphangiogenesis immunomodulation

Introduction

Vascular endothelial growth factor-C (VEGF-C) belongs to the VEGF family which, in mammals, consists of VEGF-A, placental growth factor, VEGF-B, VEGF-C, and VEGF-D.¹ Each member of the VEGF family is encoded by a different gene but shares the VEGF homology domain.² Among the VEGF family members, VEGF-C shares the highest homology with VEGF-A (∼30%),³ which is considered to be a critical angiogenic factor. VEGF-C, on the other hand, acts mainly in development- and disease-associated lymphangiogenesis. This mini-review will briefly introduce the conventional role of VEGF-C and summarize recent findings of the unconventional functions of VEGF-C and its receptors in cancer progression.

The conventional role of VEGF-C

The gene for VEGF-C was originally cloned from a cDNA library derived from the human prostatic adenocarcinoma cell line PC-3³ and encodes a protein that requires proteolytic cleavage to produce a functional secreted protein. In embryonic development, VEGF-C is required for the initial migration and sprouting of the committed endothelial cells from the primary lymph sac. Knockout of Vegfc causes prenatal death of mice due to a lack of lymphatic vessel formation.⁴ During development of the lymphatic system, expression of the tyrosine kinase receptor VEGFR-3 (FLT4) is gradually confined to lymphatic endothelial cells. This receptor is activated by the binding of VEGF-C that is produced by adjacent regions, triggering downstream signaling that can promote proliferation, migration, and survival of lymphatic endothelial cells.^5,6 In addition to VEGFR-3, fully processed forms of VEGF-C can also bind to VEGFR-2, which is also expressed on endothelial cells and activation of VEGFR-2 is mainly involved in angiogenesis.³ Besides binding to the well-known VEGFR, VEGF-C also binds to another group of transmembrane proteins, the neuropilin (NRP) family. NRP1 and NRP2 are co-receptors bound by the class 3 semaphorin (SEMA) and VEGF families, which modulate plexin and VEGFR signaling in vascular and neural development.⁷ VEGF-C binds preferentially to NRP2 compared to NRP1, and the binding of VEGF-C to NRP2 enhances VEGFR-2 or VEGFR-3 activity.⁸ NRP2 is required for the formation of small lymphatic vessels and capillaries⁹ and the expression of NRP2 augments the effects of VEGF-C-VEGFR-3 axis in lymphangiogenesis.¹⁰ The binding of VEGF-C to receptors that are expressed on lymphatic and blood vessels results in both angiogenesis and lymphangiogenesis, reflecting the complexity of VEGF-C signaling.

Pro-lymphangiogenic function of VEGF-C in cancer

Increased expression of VEGF-C in tumors and higher levels of VEGF-C in serum of cancer patients have been observed.^11–13 Enhanced expression of VEGF-C is prevalent in lymph node positive tumors and is associated with high lymphatic vessel density and poor survival such as in breast, prostate, and colon cancer.^14–19 The originally identified function of VEGF-C in cancer is similar to what has been observed in embryonic development as overexpression of VEGF-C in tumor cells induced peritumoral and intratumoral lymphangiogenesis in mouse models of breast cancer.²⁰,²¹ It is evident that increased tumor-associated lymphangiogenesis is sufficient to promote metastasis to regional lymph nodes and to distant organs.^20–22 Interestingly, in addition to promoting tumor-associated lymphangiogenesis and angiogenesis, growing evidence suggests that VEGF-C can also contribute to tumor progression by means of autocrine signaling.

Autonomous function of VEGF-C and receptors axis in cancer

Solid tumors metastasize frequently through the lymphatic system and regional lymph nodes. Overexpression of VEGF-C in cancers suggests a role of the protein in promoting lymph node metastasis via increased lymphangiogenesis. While the expression of VEGF-C receptors is limited to lymphatic endothelial cells (LECs) during development, in the context of cancer, re-expression of those receptors on tumor cells further suggests the existence of autocrine regulation by VEGF-C.

VEGF-C and VEGFR

Increased VEGF-C and VEGFR-3 expression was first demonstrated in acute myeloid leukemia (AML), the hematological cancer, suggesting a possible function of VEGF-C beyond stimulation of lymphangiogenesis.²³ Subsequent studies showed that VEGF-C can signal through VEGFR-3 expressed on the leukemic cells to regulate the pro-survival protein Bcl-2 and affect both proliferation and response of tumor cells to chemotherapy.²⁴ A very recent study in ovarian cancer also showed that inhibition of VEGFR-3 sensitized tumor cells to chemotherapy, an action which involves down-regulation of the tumor suppressor gene BRCA1/2.²⁵ In addition, VEGF-C and/or VEGFR-2/3 signals have been linked to proliferation, migration, and invasion of gallbladder cancer, esophageal cancer, breast cancer, and lung adenocarcinoma cells.^26–29

VEGF-C and neurophilin

The VEGF-C/NRP2 axis has recently been implicated in enhancing cell survival under oxidative stress and therapeutic-induced autophagy in prostate cancer cells, while different mTOR is involved as downstream effector.^30,31 In a breast cancer model, a similar antioxidant function of VEGF-C/NRP2 was observed. However, in this study, superoxide dismutase 3 was identified as the principal mediator.³² It should be noted that NRP2 lacks an intrinsic catalytic domain in the cytoplasmic tail, and therefore, no clear evidence suggests that NRP2 is capable of transducing downstream signal alone. Instead, NRP2 is required to cooperate with either conventional (plexins and VEGFRs) or unconventional receptors (such as integrins).³³ NRP2 has been shown to mediate TGFβ-induced epithelial-to-mesenchymal transition (EMT) in lung cancer cells and is required for breast tumor initiation via stimulation of integrin and focal adhesion kinase.^34,35 However, the potential involvement of VEGF-C in NRP2-mediated phenotypes in these studies was not discussed.

Emerging role of VEGF-C in cancer stemness

It is thought that the existence of a cancer stem-like cell population may be a key factor that accounts for the failure of conventional chemo- or radiotherapies. In addition to regulating the response of tumor cells to chemotherapy, VEGF-C also mediates tumor initiating ability and EMT features, which are often connected with cancer stem-like character. Inhibition of VEGF-C in lung cancer cells increased epithelial but decreased mesenchymal markers, as well as decreased side population (dye efflux property of putative cancer stem cell population) and tumorigenicity in vivo.³⁶ In breast cancer, VEGF-C level was enriched in a CD44+/CD24-/low tumor initiating population isolated from breast cancer lesions³⁷ and inhibition of VEGF-C expression decreased aldehyde dehydrogenase positive population and tumor formation.³² NRP2/integrin signaling has recently been found to promote breast tumor initiation,³⁵ implying that NRP2 might be the receptor which conducts VEGF-C-mediated stem-like phenotypes. However, the downstream signaling responsible for VEGF-C-dependent EMT and cancer stemness properties must be further determined. In Table 1, we summarize the autocrine function of VEGF-C in different human cancers.

Table 1

Selective tumor cell-autonomous function of VEGF-C axis in human cancer

Cancer type	Function/receptors or pathways involved	References
Breast	Promotes migration via VEGFR2/NRP2	27
Breast	Mediates chemoresistance and antioxidant ability via NRP2	32,79
Cervical	Promotes migration and invasion via RhoA/ROCK-2
Cervical	or NFκB pathway	80,81
Colon and lung	EMT and cancer stem-like population	36
Esophageal	Mediates proliferation, migration, and colony formation	29
Esophageal	Promotes tumor growth and metastasis via Src-microRNA	82
Gastric	Promotes invasion and chemoresistance	49
Gallbladder	Promotes proliferation and invasion via VEGFR2/VEGFR3	28
Leukemia	Promotes proliferation via COX-2	83
Leukemia	Promotes proliferation and chemoresistance via VEGFR3	24
Prostate	Mediates response to oxidative stress via NRP2	30
Prostate	Mediates autophagy and chemoresistance via NRP2	31
Ovarian	Mediates chemoresistance via VEGFR3 and	25
Ovarian	down-regulation of BRCA1/2

NRP: neuropilin; VEGF-C: vascular endothelial growth factor-C.

Immune regulatory role of VEGF-C in tumor microenvironment

The tumor microenvironment is generally considered to be associated with inflammation, and infiltrating immune cells are thought to provide a source of cytokines and growth factors which can promote tumor growth. Besides the known functions in regulating endothelial and cancer cells, VEGF-C was recently found to be expressed by immune cells or to regulate immune response. Expression of VEGF-C can be induced in tumor-associated macrophages by inflammatory cytokines secreted from tumor cells, and increased VEGF-C can in turn promote tumor-associated lymphangiogenesis and metastasis.^38,39 A negative correlation of VEGF-C with tumor-infiltrating dendritic cells has been observed in gastric cancer,⁴⁰ implying a role for VEGF-C in immune modulation. Natural killer (NK) cells from AML patients express higher levels of VEGFR-3 and inhibition of VEGFR-3 restored cytotoxic activity of the AML-NK cells^41,42 further supporting the importance of VEGF-C-VEGFR-3 axis in tumor immunity. Another study in a mouse mammary carcinoma model showed that knockdown of VEGF-C switches the infiltration and phenotype of T cell and dendritic cells toward an antitumor environment.⁴³ Similarly, VEGF-C has been demonstrated to promote immune tolerance via suppression of CD8+ T cells in draining lymph nodes of melanoma.⁴⁴ Together, these studies reveal a potential function of VEGF-C as an immunomodulator and provides a mechanism by which tumor cells escape immune surveillance.

Regulation of VEGF-C expression

In mouse embryos, VEGF-C mRNA expression was enriched in mesenchymal cells and regions where lymphatic vessels were sprouting.⁴⁵ Although the mechanism by which VEGF-C is expressed in development is largely unknown, studies in cancer provide evidence for how VEGF-C can be regulated.

Transcription factor

Homeoproteins are transcription factors that are highly conserved among species and are considered to be the master regulators in embryogenesis. The expression of prostate-specific homeobox protein NKX3.1 is lost in prostate cancer and has been shown to inhibit VEGF-C expression by cooperating with histone deacetylase.⁴⁶ Sine oculis homeobox homolog 1 (SIX1), which is highly expressed in metastatic breast cancer cells, activates VEGF-C transcription and promotes lymph node metastasis.⁴⁷ Many other transcription factors, such as chicken ovalbumin upstream promoter transcription factor 2 (COUP-TFII), inhibitor of differentiation/DNA binding factor (Id-1), Rho GDP dissociation inhibitor 2 (RhoGDI2), and high mobility group box 1 (HMGB1) can also regulate the expression of VEGF-C.^48–51 However, whether the regulation is mediated by direct binding to the VEGF-C promoter warrants further investigation.

Cytokines, growth factors, and extracellular matrix (ECM)

Analysis of the VEGF-C promoter led to the identification of putative binding sites for NFκB, implying a mechanism by which inflammatory stimuli may control VEGF-C expression.⁵² Indeed, pro-inflammatory factors such as interleukin 1β (IL-1β) and IL-6 increased VEGF-C mRNA expression⁵³; in addition, growth factors such as PDGF, EGF, or TGFβ can also activate VEGF-C expression.^54,55 Co-expression of cyclooxygenase (COX)-2 and VEGF-C has been reported in several cancers and further evidence indicates that COX-2 derived prostaglandin E₂ (PGE₂)-EP receptors is another mechanism by which VEGF-C expression is regulated.^56–58

Components in the ECM have also been shown to regulate VEGF-C expression. Heparanase, an endoglycosidase which cleaves heparan sulfate in the ECM, participating in ECM remodeling and degradation, can stimulate VEGF-C expression and promote tumor lymphangiogenesis.⁵⁹ Furthermore, induction of VEGF-C by extra domain A, an alternative splicing domain of fibronectin, has been shown in colorectal cancer cells.⁶⁰ Overall, VEGF-C expression can be activated by a wide range of signaling pathway including, P38-NFκB, phosphoinositide 3-kinase-Akt, or MAPK signaling, though the specific mechanisms depend on the individual stimuli and cellular context.^53,61,62

Post-transcriptional, translational, and epigenetic regulation

MicroRNA is an emerging mechanism by which gene expression is regulated at a post-transcriptional level. Tumor suppressor microRNAs, miR-1862, miR27b, and miR128^63–65 have been found to target VEGF-C and inhibit tumor progression. While there is no putative hypoxia responsive binding site on the VEGF-C promoter and a previous study showed that VEGF-C mRNA does not change under hypoxic conditions,⁵⁴ a very recent study demonstrated that VEGF-C protein is increased in tumors and this is mediated in an internal ribosome entry site (IRES)-dependent manner.⁶⁶ In addition, it has been found that in gastric cancer cell lines, expression of VEGF-C was inversely correlated with VEGF-C promoter methylation status. Moreover, treatment with a methyl donor S-adenosylmethionine induced VEGF-C methylation, leading to a decrease in VEGF-C expression.⁶⁷ However, whether hypomethylation of VEGF-C leads to its overexpression in other types of cancer remains to be evaluated.

It should be noted that the specificity and activity VEGF-C can be regulated by post-translational processing (proteolytic cleavage).⁶⁸ Proprotein convertase furin, PC5, and PC7 have all been identified as VEGF-C candidate convertases,⁶⁹ providing an additional mechanism by which VEGF-C can be functionally regulated.

Conclusion and perspectives

VEGF-C is an important factor in promoting lymphangiogenesis and lymph node metastasis of cancer cells. In addition, VEGF-C displays multifunctional roles in cancer progression and thus warrants increased attention. Because VEGF-C can affect endothelial cells, tumor cells, and immune cells (Figure 1), researchers are seeking methodologies to block VEGF-C signaling by various mechanisms, including an anti-VEGF-C antibody, a soluble receptor mimic that traps VEGF-C, an antibody that interferes with VEGF-C/receptor interaction, or inhibitors that target VEGFR tyrosine kinase activity.^70–74 While targeting the VEGF-C-receptor axis is a direct way to inhibit VEGF-C mediated effects, understanding the mechanism by which VEGF-C is up-regulated in cancer may provide additional strategies for cancer treatment. For example, since COX-2-PGE₂ regulates VEGF-C expression, inhibitors of COX-2 may also effectively inhibit VEGF-C-mediated lymphangiogenesis and metastasis.

Figure 1

Multiple functions of VEGF-C in tumor progression. VEGF-C binds to receptors expressed on endothelial cells and promotes angiogenesis and lymphangiogenesis. Tumor cells which express VEGFR-2, VEGFR-3, and NRP2 can receive VEGF-C autocrine signals and trigger downstream pathway which mediates aggressive phenotypes. Tumor-associated macrophages are another source of VEGF-C which contributes to the increased expression of VEGF-C in the microenvironment. Immune cells, such as NK cells, can receive VEGF-C signal and thus exhibit immune suppressive functions which favor tumor progression. VEGF-C: vascular endothelial growth factor-C. (A color version of this figure is available in the online journal.)

In breast cancer, overexpression of VEGF-C is known to be associated with lymph node metastasis.^75,76 Moreover, a recent study showed that VEGF-C mRNA expression is specifically enriched in the claudin-low subtype of breast cancer, an aggressive subtype that confers poor prognosis and for which almost no target therapy exists.³² Since inhibition of VEGF-C sensitizes tumor cells to chemotherapies, it is possible that inhibition of VEGF-C may increase current treatment efficacy specifically in this subtype of breast cancer. Therefore, combination of anti-VEGF-C with other therapies may be applied to cancer patients even when lymphangiogenesis/lymph node metastasis is not involved.

Current evidence indicates VEGF-C plays an important role in promoting cancer progression via paracrine and autocrine mechanisms, making VEGF-C axis an attractive target to inhibit tumor progression. Additionally, VEGF-C expression has been demonstrated to sensitize lymphatic endothelial cells to radiation-induced cell quiescence, which may account for lymphedema in breast cancer patients after radiotherapy.⁷⁷ Therefore, blocking VEGF-C signaling in conjunction with other treatments as anticancer therapy may be able to “kill two (or more) birds with one stone.” However, since VEGF-C binds to multiple receptors to trigger different downstream signaling pathways and up-regulation of VEGF-C has been observed in tumor cells that have acquired resistance to anti-VEGF therapy,⁷⁸ targeting VEGF-C as an anticancer therapy may be more difficult than one would anticipate. Therefore, potential disadvantages of anti-VEGF-C therapeutics should be taken into consideration when it comes to clinical application.

Footnotes

Authors’ contributions

CA-W drafted and edited the manuscript. SJ-T edited and finalized the manuscript.

ACKNOWLEDGEMENTS

We apologize to those authors whose work has not been cited. We thank Dr Marcus J. Calkins for proofreading of this current manuscript. Chu-An Wang is funded by grant from Ministry of Sciences and Technology, Taiwan (MOST 103-2321-B-006-020-MY3). Shaw-Jenq Tsai is funded by grants from National Research Program for Biopharmaceuticals (NSC 101-2325-B-006-017), National Health Research Institute (NHRI-EX-102-10244BI), and Top University grant of National Cheng Kung University (D103-35A17).

References

Lohela

Bry

Tammela

Alitalo

. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009; 21: 154–65.

Otrock

Makarem

Shamseddine

. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis 2007; 38: 258–68.

Joukov

Pajusola

Kaipainen

Chilov

Lahtinen

Kukk

Saksela

Kalkkinen

Alitalo

. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996; 15: 290–98.

Karkkainen

Haiko

Sainio

Partanen

Taipale

Petrova

Jeltsch

Jackson

Talikka

Rauvala

Betsholtz

Alitalo

. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nature Immunol 2004; 5: 74–80.

Makinen

Veikkola

Mustjoki

Karpanen

Catimel

Nice

Wise

Mercer

Kowalski

Kerjaschki

Stacker

Achen

Alitalo

. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 2001; 20: 4762–73.

Salameh

Galvagni

Bardelli

Bussolino

Oliviero

. Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. Blood 2005; 106: 3423–31.

Prud’homme

Glinka

. Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity. Oncotarget 2012; 3: 921–39.

Favier

Alam

Barron

Bonnin

Laboudie

Fons

Mandron

Herault

Neufeld

Savi

Herbert

Bono

. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood 2006; 108: 1243–50.

Mas

. Seminars in cell and developmental biology. Plant circadian rhythms. Preface. Semin Cell Dev Biol 2013; 24: 381–2.

10.

Yuan

Mak

Pardanaud

Caunt

Kasman

Larrivee

Del Toro

Suchting

Medvinsky

Silva

Yang

Thomas

Koch

Alitalo

Eichmann

Bagri

. Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J Cell Biol 2010; 188: 115–30.

11.

Decio

Taraboletti

Patton

Alzani

Perego

Fruscio

Jurgensmeier

Giavazzi

Belotti

. Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms. Am J Pathol 2014; 184: 1050–61.

12.

Kinoshita

Kitamura

Kabashima

Saeki

Tanaka

Sugimachi

. Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat 2001; 66: 159–64.

13.

Kimura

Kato

Tanaka

Inose

Faried

Sohda

Nakajima

Fukai

Miyazaki

Masuda

Manda

Fukuchi

Ojima

Tsukada

Kuwano

. Preoperative serum vascular endothelial growth factor-C (VEGF-C) levels predict recurrence in patients with esophageal cancer. Anticancer Res 2008; 28: 165–9.

14.

Mohammed

Green

El-Shikh

Paish

Ellis

Martin

. Prognostic significance of vascular endothelial cell growth factors-A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. Br J Cancer 2007; 96: 1092–100.

15.

Kigure

Fujii

Sutoh

Morita

Katoh

Yajima

Yamaguchi

Tsutsumi

Asao

Kuwano

. The association of VEGF-C expression with tumor lymphatic vessel density and lymph node metastasis in patients with gastric cancer and gastrointestinal stromal tumor. Hepato-gastroenterology 2013; 60: 277–80.

16.

Zhao

Wang

Zha

Zhao

Wang

. Tumor-derived VEGF-C, but not VEGF-D, promotes sentinel lymph node lymphangiogenesis prior to metastasis in breast cancer patients. Med Oncol 2012; 29: 2594–600.

17.

Tanaka

Ishiguro

Kuwabara

Kimura

Mitsui

Katada

Shiozaki

Naganawa

Fujii

Takeyama

. Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis. J Exp Clin Cancer Res 2010; 29: 83–83.

18.

Jennbacken

Vallbo

Wang

Damber

. Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate 2005; 65: 110–6.

19.

Soumaoro

Uetake

Takagi

Iida

Higuchi

Yasuno

Enomoto

Sugihara

. Coexpression of VEGF-C and Cox-2 in human colorectal cancer and its association with lymph node metastasis. Dis Colon Rectum 2006; 49: 392–8.

20.

Skobe

Hawighorst

Jackson

Prevo

Janes

Velasco

Riccardi

Alitalo

Claffey

Detmar

. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nature Med 2001; 7: 192–8.

21.

Mattila

Ruohola

Karpanen

Jackson

Alitalo

Harkonen

. VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int J Cancer 2002; 98: 946–51.

22.

Rinderknecht

Detmar

. Tumor lymphangiogenesis and melanoma metastasis. J Cell Physiol 2008; 216: 347–54.

23.

Fielder

Graeven

Ergun

Verago

Kilic

Stockschlader

Hossfeld

. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia 1997; 11: 1234–7.

24.

Dias

Choy

Alitalo

Rafii

. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 2002; 99: 2179–84.

25.

Lim

Yang

Taylor-Harding

Wiedemeyer

Buckanovich

. VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2. Neoplasia 2014; 16: 343–53.

26.

Yang

Shih

Yang

Wei

Hsieh

Chou

Jeng

Wang

Chang

Hung

Kuo

. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell 2006; 9: 209–23.

27.

Timoshenko

Rastogi

Lala

. Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells. Br J Cancer 2007; 97: 1090–8.

28.

Chen

Jiang

She

Tang

Wang

Han

Zhu

. Vascular endothelial growth factor-C promotes the growth and invasion of gallbladder cancer via an autocrine mechanism. Mol Cell Biochem 2010; 345: 77–89.

29.

Liu

Zhou

Zhu

Xie

Wang

Liu

Shen

Xiang

Zhu

Shi

Zhang

. VEGF-C promotes the development of esophageal cancer via regulating CNTN-1 expression. Cytokine 2011; 55: 8–17.

30.

Muders

Zhang

Wang

Tindall

Datta

. Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1. Cancer Res 2009; 69: 6042–8.

31.

Stanton

Dutta

Zhang

Polavaram

Leontovich

Honscheid

Sinicrope

Tindall

Muders

Datta

. Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance. Cancer Res 2013; 73: 160–71.

32.

Wang

Harrell

Iwanaga

Jedlicka

Ford

. Vascular endothelial growth factor-C promotes breast cancer progression via a novel anti-oxidant mechanism that involves regulation of Superoxide dismutase 3. Breast Cancer Res 2014; 16: 462–462.

33.

Cao

Hoeppner

Bach

Guo

Wang

Cowley

Chang

Waddell

Grimmond

Biankin

Daly

Zhang

Mukhopadhyay

. Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial alpha5 integrin. Cancer Res 2013; 73: 4579–90.

34.

Nasarre

Gemmill

Potiron

Roche

Baron

Korch

Garrett-Mayer

Lagana

Howe

Drabkin

. Neuropilin-2 Is upregulated in lung cancer cells during TGF-beta1-induced epithelial-mesenchymal transition. Cancer Res 2013; 73: 7111–21.

35.

Goel

Pursell

Chang

Shaw

Mao

Simin

Kumar

Vander Kooi

Shultz

Greiner

Norum

Toftgard

Kuperwasser

Mercurio

. GLI1 regulates a novel neuropilin-2/alpha6beta1 integrin based autocrine pathway that contributes to breast cancer initiation. EMBO Mol Med 2013; 5: 488–508.

36.

Khromova

Kopnin

Rybko

Kopnin

. Downregulation of VEGF-C expression in lung and colon cancer cells decelerates tumor growth and inhibits metastasis via multiple mechanisms. Oncogene 2012; 31: 1389–97.

37.

Ponti

Costa

Zaffaroni

Pratesi

Petrangolini

Coradini

Pilotti

Pierotti

Daidone

. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005; 65: 5506–11.

38.

Ding

Tan

Wang

Chen

Ding

. The effect of vascular endothelial growth factor C expression in tumor-associated macrophages on lymphangiogenesis and lymphatic metastasis in breast cancer. Mol Med Rep 2012; 6: 1023–9.

39.

Peppicelli

Bianchini

Calorini

. Inflammatory cytokines induce vascular endothelial growth factor-C expression in melanoma-associated macrophages and stimulate melanoma lymph node metastasis. Oncol Lett 2014; 8: 1133–8.

40.

Takahashi

Kono

Itakura

Amemiya

Feng Tang

Iizuka

Fujii

Matsumoto

. Correlation of vascular endothelial growth factor-C expression with tumor-infiltrating dendritic cells in gastric cancer. Oncology 2002; 62: 121–7.

41.

Lee

Park

Kim

Yoon

Shin

Min

Kim

. A VEGFR-3 antagonist increases IFN-gamma expression on low functioning NK cells in acute myeloid leukemia. J Clin Immunol 2013; 33: 826–37.

42.

Lee

Park

Min

Kim

. Restoration of natural killer cell cytotoxicity by VEGFR-3 inhibition in myelogenous leukemia. Cancer Lett 2014; 354: 281–9.

43.

Chen

Varney

Backora

Cowan

Solheim

Talmadge

Singh

. Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. Cancer Res 2005; 65: 9004–11.

44.

Lund

Duraes

Hirosue

Raghavan

Nembrini

Thomas

Issa

Hugues

Swartz

. VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. Cell Rep 2012; 1: 191–9.

45.

Kukk

Lymboussaki

Taira

Kaipainen

Jeltsch

Joukov

Alitalo

. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 1996; 122: 3829–37.

46.

Zhang

Muders

Rinaldo

Tindall

Datta

. Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancer. Cancer Res 2008; 68: 8770–8.

47.

Wang

Jedlicka

Patrick

Micalizzi

Lemmer

Deitsch

Casas-Selves

Harrell

Ford

. SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer. J Clin Invest 2012; 122: 1895–906.

48.

Lin

Chen

Qin

Hong

Tsai

. Direct transcriptional regulation of neuropilin-2 by COUP-TFII modulates multiple steps in murine lymphatic vessel development. J Clin Invest 2010; 120: 1694–707.

49.

Cho

Kim

Park

Baek

Nam

Park

Ryu

Choi

Ryu

Hong

Jeong

Lee

Kim

Won Lee

Soo Kang

Yoo

. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance. Int J Cancer 2014; 135: 1553–63.

50.

Dong

Wei

Zhou

Sumida

Hamakawa

Liu

. Silencing Id-1 inhibits lymphangiogenesis through down-regulation of VEGF-C in oral squamous cell carcinoma. Oral Oncol 2011; 47: 27–32.

51.

Chen

Tang

. [Effect of HMGB1 on the VEGF-C expression and proliferation of esophageal squamous cancer cells]. Zhonghua Zhong Liu Za Zhi [Chinese J Oncol] 2012; 34: 566–70.

52.

Olofsson

Pajusola

von Euler

Chilov

Alitalo

Eriksson

. Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform. J Biol Chem 1996; 271: 19310–7.

53.

Shinriki

Jono

Ueda

Ota

Sueyoshi

Oike

Ibusuki

Hiraki

Nakayama

Shinohara

Ando

. Interleukin-6 signalling regulates vascular endothelial growth factor-C synthesis and lymphangiogenesis in human oral squamous cell carcinoma. J Pathol 2011; 225: 142–50.

54.

Enholm

Paavonen

Ristimaki

Kumar

Gunji

Klefstrom

Kivinen

Laiho

Olofsson

Joukov

Eriksson

Alitalo

. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 1997; 14: 2475–83.

55.

Ristimaki

Narko

Enholm

Joukov

Alitalo

. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem 1998; 273: 8413–8.

56.

von Rahden

Stein

Puhringer

Koch

Langer

Piontek

Siewert

Hofler

Sarbia

. Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res 2005; 65: 5038–44.

57.

Timoshenko

Chakraborty

Wagner

Lala

. COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br J Cancer 2006; 94: 1154–63.

58.

Liu

Xiao

Yang

Liu

Deng

Zhang

. COX-2 expression is correlated with VEGF-C, lymphangiogenesis and lymph node metastasis in human cervical cancer. Microvasc Res 2011; 82: 131–40.

59.

Cohen-Kaplan

Naroditsky

Zetser

Ilan

Vlodavsky

Doweck

. Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer 2008; 123: 2566–73.

60.

Xiang

Xie

Wei

Pan

Liang

. The extra domain A of fibronectin increases VEGF-C expression in colorectal carcinoma involving the PI3K/AKT signaling pathway. PLoS One 2012; 7: e35378–e35378.

61.

Luangdilok

Box

Harrington

Rhys-Evans

Eccles

. MAPK and PI3K signalling differentially regulate angiogenic and lymphangiogenic cytokine secretion in squamous cell carcinoma of the head and neck. Eur J Cancer 2011; 47: 520–9.

62.

Tsai

Shiah

Lin

Kuo

. Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathway. J Biol Chem 2003; 278: 5750–9.

63.

Zhang

Chen

Qiu

Huang

. miRNA-27b targets vascular endothelial growth factor C to inhibit tumor progression and angiogenesis in colorectal cancer. PLoS One 2013; 8: e60687–e60687.

64.

Hirata

Hinoda

Ueno

Shahryari

Tabatabai

Dahiya

. MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer. Carcinogenesis 2012; 33: 41–8.

65.

Cheng

Jin

Pan

Liu

Zhang

Feng

. microRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C. Eur J Cancer 2014; 50: 2336–50.

66.

Morfoisse

Kuchnio

Frainay

Gomez-Brouchet

Delisle

Marzi

Helfer

Hantelys

Pujol

Guillermet-Guibert

Bousquet

Dewerchin

Pyronnet

Prats

Carmeliet

Garmy-Susini

. Hypoxia induces VEGF-C expression in metastatic tumor cells via a HIF-1alpha-independent translation-mediated mechanism. Cell Rep 2014; 6: 155–67.

67.

Matsumura

Oue

Mitani

Kitadai

Yasui

. DNA demethylation of vascular endothelial growth factor-C is associated with gene expression and its possible involvement of lymphangiogenesis in gastric cancer. Int J Cancer 2007; 120: 1689–95.

68.

Joukov

Sorsa

Kumar

Jeltsch

Claesson-Welsh

Cao

Saksela

Kalkkinen

Alitalo

. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 1997; 16: 3898–911.

69.

Siegfried

Basak

Cromlish

Benjannet

Marcinkiewicz

Chretien

Seidah

Khatib

. The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J Clin Invest 2003; 111: 1723–32.

70.

Zheng

Aspelund

Alitalo

. Lymphangiogenic factors, mechanisms, and applications. J Clin Invest 2014; 124: 878–87.

71.

Chen

Chang

Hong

. The role of the VEGF-C/VEGFRs Axis in tumor progression and therapy. Int J Mol Sci 2012; 14: 88–107.

72.

Kozaki

Karpanen

Koshikawa

Yla-Herttuala

Takahashi

Alitalo

. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 2002; 94: 819–25.

73.

Roberts

Kloos

Cassella

Podgrabinska

Persaud

Pytowski

Skobe

. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 2006; 66: 2650–7.

74.

Parker

Vander Kooi

. Microplate-based screening for small molecule inhibitors of neuropilin-2/vascular endothelial growth factor-C interactions. Anal Biochem 2014; 453: 4–6.

75.

Zhao

Dai

Yuan

Zhu

Luo

. Peritumoral lymphangiogenesis induced by vascular endothelial growth factor C and D promotes lymph node metastasis in breast cancer patients. World J Surg Oncol 2012; 10: 165–165.

76.

Koyama

Kaneko

Akazawa

Kanbayashi

Kanda

Hatakeyama

. Vascular endothelial growth factor-C and vascular endothelial growth factor-d messenger RNA expression in breast cancer: association with lymph node metastasis. Clin Breast Cancer 2003; 4: 354–60.

77.

Kesler

Kuo

Wong

Masuck

Shah

Kozak

Held

Padera

. Vascular endothelial growth factor-C enhances radiosensitivity of lymphatic endothelial cells. Angiogenesis 2014; 17: 419–27.

78.

Xie

Ding

Chen

Qian

Jiang

Fang

. Tumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression. Cancer Lett 2014; 346: 45–52.

79.

Sun

Gao

Liu

Wei

Liu

. RNA interference (RNAi)-mediated vascular endothelial growth factor-C (VEGF-C) reduction interferes with lymphangiogenesis and enhances epirubicin sensitivity of breast cancer cells. Mol Cell Biochem 2008; 308: 161–8.

80.

Cheng

Liu

Huang

. Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. BMC Cancer 2010; 10: 170–170.

81.

Chen

Suo

Cheng

Zheng

. Vascular endothelial growth factor C enhances cervical cancer migration and invasion via activation of focal adhesion kinase. Gynecol Endocrinol 2013; 29: 20–4.

82.

Su CM, Su YH, Chiu CF, Chang YW, Hong CC, Yu YH, Ho YS, Wu CH, Yen CS, Su JL. Vascular endothelial growth factor-C upregulates cortactin and promotes metastasis of esophageal squamous cell carcinoma. Ann Surg Oncol 2014;21:767-775.

83.

Hua

Lee

Yang

Chen

Hsiao

Wei

Kuo

Chien

. Vascular endothelial growth factor-C modulates proliferation and chemoresistance in acute myeloid leukemic cells through an endothelin-1-dependent induction of cyclooxygenase-2. Biochim Biophys Acta 2014; 1843: 387–97.